Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 2/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
| ▸ | SLC6A2 | P23975 | 2/20 | 0.41 |
| ▸ | SLC6A4 | P31645 | 2/20 | 0.41 |
| ▸ | SLC6A3 | Q01959 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.41 |
| ▸ | CYP19A1 | P11511 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.36 |
| ▸ | NOS1 | P29475 | 1/20 | 0.36 |
| ▸ | MAPT | P10636 | 2/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.35 |
| ▸ | CYP17A1 | P05093 | 2/20 | 0.33 |
| ▸ | PABPC1 | P11940 | 1/20 | 0.33 |
| ▸ | APOBEC3A | P31941 | 1/20 | 0.33 |
| ▸ | EIF4H | Q15056 | 1/20 | 0.33 |
| ▸ | APOBEC3G | Q9HC16 | 1/20 | 0.33 |
| ▸ | CYP11B1 | P15538 | 1/20 | 0.33 |
| ▸ | CYP11B2 | P19099 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4261122 | 0.78 | CYP3A4 (0.43) | CYP3A4CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL18812091 | 0.78 | CYP3A4 (0.43) | CYP3A4CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL1145689 | 0.74 | KMT2A (0.44) | CYP3A4CYP2C19SLC6A4SLC6A3KMT2A | |
| SCHEMBL14535430 | 0.74 | KMT2A (0.44) | CYP3A4CYP2C19SLC6A4SLC6A3KMT2A | |
| SCHEMBL20809867 | 0.74 | KMT2A (0.44) | CYP3A4CYP2C19SLC6A4SLC6A3KMT2A | |
| SCHEMBL24849599 | 0.74 | TYR (0.42) | GAANOS1LMNA | |
| SCHEMBL8041464 | 0.73 | CYP3A4 (0.43) | CYP3A4CYP2C19SLC6A2SLC6A4SLC6A3 | |
| SCHEMBL21892893 | 0.73 | CFTR (0.50) | SLC6A2SLC6A4SLC6A3GAACYP19A1 | |
| SCHEMBL23773705 | 0.73 | CFTR (0.50) | SLC6A2SLC6A4SLC6A3GAACYP19A1 | |
| SCHEMBL724559 | 0.73 | CYP3A4 (0.52) | CYP3A4CYP2C19SLC6A2SLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11136316-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the Human Immunodeficiency Virus | YALE UNIVERSITY (US) | 2021-10-05 | — | — | US | disclosed |
| US-20200392121-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-12-17 | — | — | US | disclosed |
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | SHY Therapeutics LLC | 2019-03-05 | — | — | US | disclosed |
| US-10000522-B2 | Derivatives of uridine 5′-cyclophosphate useful to treat hepatitis C viral infections | LIGAND PHARMACEUTICALS INCORPORATED (US) | 2018-06-19 | — | — | US | disclosed |
| US-20170334942-A1 | DERIVATIVES OF URIDINE 5'-CYCLOPHOSPHATE USEFUL TO TREAT HEPATITIS C VIRAL INFECTIONS | CITIBANK, N.A., AS ADMINISTRATIVE AGENT | 2017-11-23 | — | — | US | disclosed |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | AMGEN INC. | 2017-10-05 | — | — | US | disclosed |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | SHY Therapeutics LLC | 2017-06-22 | — | — | US | disclosed |
| US-5422353-A | Alzheimer*s disease, glaucoma treatment | BOEHRINGER INGELHEIM KG (DE) | 1995-06-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10221191-B2 | Compounds for the treatment of cancer and inflammatory disease | MAPK6, MAP3K6, MAPK4 | CYP3A4 4589/4885CYP2C19 4701/4885SLC6A2 4742/4885 |
| US-10000522-B2 | Derivatives of uridine 5′-cyclophosphate useful to treat hepatitis C viral infections | UMPS, NUDT14, PNP | CYP3A4 1262/4885CYP2C19 2292/4885SLC6A2 3955/4885 |
| US-20200392121-A1 | BIFUNCTIONAL MOLECULES WITH ANTIBODY-RECRUITING AND ENTRY INHIBITORY ACTIVITY AGAINST THE HUMAN IMMUNODEFICIENCY VIRUS | CD4, HAVCR2, CD2 | CYP3A4 3032/4885CYP2C19 4511/4885SLC6A2 1888/4885 |
| US-11136316-B2 | Bifunctional molecules with antibody-recruiting and entry inhibitory activity against the Human Immunodeficiency Virus | CD4, HAVCR2, CD2 | CYP3A4 3032/4885CYP2C19 4511/4885SLC6A2 1888/4885 |
| US-20170334942-A1 | DERIVATIVES OF URIDINE 5'-CYCLOPHOSPHATE USEFUL TO TREAT HEPATITIS C VIRAL INFECTIONS | UMPS, NUDT14, PNP | CYP3A4 1189/4885CYP2C19 2170/4885SLC6A2 3945/4885 |
| US-20170281625-A1 | METHODS OF TREATING HEART FAILURE | FABP3, TNNI3, APLNR | CYP3A4 3671/4885CYP2C19 2697/4885SLC6A2 881/4885 |
| US-20170174699-A1 | COMPOUNDS FOR THE TREATMENT OF CANCER AND INFLAMMATORY DISEASE | MAPK6, MAP3K6, MAPK4 | CYP3A4 4589/4885CYP2C19 4701/4885SLC6A2 4742/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.